Judo Bio
Updated: February 26, 2026
CEO - Rajiv Patni
Country: USA | Funding: $100M (+)
Founded: 2021
Website: https://judo.bio/
Judo Bio develops kidney-delivered oligonucleotide therapies for renal diseases. Its STRIKE (Selectively Targeting RNA Into KidnEy) platform utilizes a proprietary approach based on a natural endogenous mechanism to deliver siRNA drugs to specific kidney cell types. Its initial drug development programs are ligand-siRNA conjugates designed for receptor-mediated uptake by specific kidney cell types, resulting in the suppression of target genes that modify the course of systemic diseases, potentially including inborn errors of metabolism, gout, hypertension, type 2 diabetes, chronic heart failure, nephrolithiasis and other endocrine disorders.
Founded: 2021
Website: https://judo.bio/
Judo Bio develops kidney-delivered oligonucleotide therapies for renal diseases. Its STRIKE (Selectively Targeting RNA Into KidnEy) platform utilizes a proprietary approach based on a natural endogenous mechanism to deliver siRNA drugs to specific kidney cell types. Its initial drug development programs are ligand-siRNA conjugates designed for receptor-mediated uptake by specific kidney cell types, resulting in the suppression of target genes that modify the course of systemic diseases, potentially including inborn errors of metabolism, gout, hypertension, type 2 diabetes, chronic heart failure, nephrolithiasis and other endocrine disorders.
